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SUMMARY
Background
Gastro-oesophageal reflux disease (GERD) is difficult to diagnose without invasive testing. 
Peptest is a newly marketed diagnostic tool which aims to quantify salivary pepsin as a 
marker of reflux, providing a rapid alternative to invasive procedures. We aimed to evaluate 
optimal timing for sampling and to evaluate the accuracy of Peptest against an independent 
measure. 
Methods
Thirty diagnosed GERD patients (12 female, mean age 49 (range 20-72)) and twenty 
asymptomatic subjects (14 female, mean age 56 (range 21-56)) were subject to diurnal 
saliva sampling, with additional samples for sixty minutes following self-reported reflux 
symptoms and following triggering of a proximal reflux alarm. Saliva samples were split and 
were analysed by both Peptest and ELISA with operators for each blinded to sample identity.
Results
Salivary pepsin was detectable in most patients and most volunteers. Peptest scores were 
significantly lower for patients than controls (P<0.005). ELISA scores showed no difference 
between patients and controls. There was no effect of diurnal sampling time (P=0.75) or time 
after symptoms (P=0.76) on Peptest readout. There was no correlation between Peptest and 
Pepsin ELISA (P=0.55); Bland-Altman analysis suggested no agreement between the tests 
(P=0.414) implying that they do not measure the same analyte. Receiver-operator curve 
suggests that neither Peptest (P=0.3328) nor pepsin (P=0.4476) is useful for predicting 
GERD .
Conclusions
Salivary pepsin is not a reliable tool for the diagnosis of GERD.
198 words
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INTRODUCTION
Gastro-esophageal reflux disease (GERD) is one of the most common gastrointestinal 
disorders and is defined as a condition that develops when the reflux of stomach contents 
causes troublesome symptoms and/or complications  1. Although the typical symptoms that 
accompany reflux into the oesophagus are heartburn and acid regurgitation, non-specific 
symptoms are not uncommon 1. Furthermore, when gastric refluxate passes the upper 
esophageal sphincter (EOR) a range of laryngeal, pharyngeal and respiratory symptoms 
including cough and recurrent infections may result 2. 
Current diagnostic methods for GERD include symptomatic assessment (including 
structured questionnaires 3, therapeutic trials with proton pump inhibitors 4,5, endoscopy 6 
and ambulatory esophageal reflux monitoring 7). Unfortunately, all have limited sensitivity 
and specificity 6 furthermore the latter two are invasive. There is therefore an unmet need for 
non-invasive diagnostic tools with good sensitivity and specificity for this condition. 
Pepsin is a protease which is synthesised, via its precursor pepsinogen, in gastric chief cells 
8 and its presence in the oesophagus or more proximal sites is argued to be indicative of 
reflux 9. Interestingly pepsin has been reported in laryngeal and nasal sinus tissues, tracheal 
secretions and broncho-alveolar lavage fluid and in saliva 9.  
Recent reports have suggested that salivary and/or sputum pepsin may be a clinically useful, 
non-invasive diagnostic marker for GERD. A commercially developed lateral flow test device 
for detecting and quantifying pepsin as a biomarker of reflux in saliva and sputum samples 
has been released. Although no definitive evaluation is available in the peer-reviewed 
literature, the five studies using it to date have yielded conflicting results 10-14 and NICE 
remains cautious about endorsing its use. Peptest comes with little information on the 
optimal timing for sampling, persistence of pepsin in the mouth following reflux, or indicative 
limits of detection, or discriminatory potential from the normal population.  The aim of this 
study was to assess the best time to take samples for salivary pepsin assay and to validate 
the findings against both conventional reflux testing and against a validatable pepsin assay 
in both GERD patients and normal volunteers.
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METHODS
Study Design
This was a case-control comparison of a commercial diagnostic assay. Cases were 
symptomatic patients referred for anti-reflux surgery, controls were asymptomatic volunteers. 
The study had two parts: (i) an initial pilot assessed feasibility of diurnal repeated saliva 
sampling, collection and posting on the day of return by the patient, all following 
manufacturer recommendations, in 10 cases and 10 controls; (ii) an extended study using 
the same sampling and storage protocol in a further 20 cases and 10 controls, with samples 
split and also analysed by a second independent method. 
Subjects 
Studies were performed on asymptomatic healthy volunteers and patients referred for 
consideration of anti-reflux surgery. Healthy volunteers were recruited by advertisements 
placed in Sheffield Teaching Hospital NHS Trusts. Volunteers with a history of upper 
gastrointestinal symptoms or those taking medications known to influence upper 
gastrointestinal function were excluded. Patients were recruited from referrals to the 
Gastrointestinal Physiology Unit for esophageal reflux and motility testing prior to 
consideration of a surgical antireflux procedure. All had typical reflux symptoms and had had 
a good or partial response to proton pump inhibitor treatment. Patients known to have other 
non-reflux related upper gastrointestinal disease or general disorders or drugs (other than 
acid suppression) known to influence upper gastrointestinal function were excluded. The 
study was approved by the Sheffield Teaching Hospital NHS Ethics Committee (NRES 
Committee Yorkshire & Humber 12/ YH/0466) and Sheffield Research Department 
(STH16373).
Study Protocol  
Following written informed consent all subjects underwent a detailed symptom assessment 
and drug history and were asked to complete two validated symptom questionnaires which 
have a high sensitivity for reflux disease (the Gastro-esophageal Reflux Score Questionnaire 
(GORS) 3 and the Hull Reflux Cough Questionnaire (HARQ) 15. Selection was based on 
positive GORS 9G$: with HARQ 9G!: included for broader assessment of symptoms. Clinical 
discussion occurred on the day to confirm the symptoms described by patients agreed with 
scores before inclusion. All participants were studied off proton pump inhibitor therapy for at 
least 7 days (pharmacokinetic analysis of PPI suggests that clearance occurs with a 60 
minutes half-life, and furthermore that PPs have a half-life of 56hr and a daily turnover rate 
of 20%, supporting 7 days as an adequate wash-out window16 in line with previous 
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assessments of Peptest17), H2RAs for 2 days and over the counter antacids and alginates for 
24 hours. 
Subjects were asked to fast for 4 hours prior to study and then underwent high-resolution 
esophageal manometry and 24-hour dual pH testing and produced saliva samples for pepsin 
analysis as detailed below.  
High resolution manometry was performed using Manoscan equipment (Sierra Scientific 
Instruments, Los Angeles USA). Esophageal pH testing was performed using a dual channel 
pH catheter (Versaflex®Given Imaging, Mansfield USA) attached to a novel data logger/ 
alarm device (PDTronics, Sheffield, UK). Since acid reflux episodes are often asymptomatic 
we developed a device to fulfil the normal functions of a pH datalogger but also produce an 
audible and visible alarm when the proximal pH channel fell below pH 4. This prompted the 
subjects to start collecting saliva samples following the first detected proximal acid reflux 
events. Following interim analysis of the 10 volunteers and 10 patients, esophageal 
impedance was additionally performed using the Sandhill system (Sandhill Scientific 
(Diversatek Healthcare, Milwalkee USA). Prior to the 24 hour study, pH catheters were 
placed such that the sensors were 5 and 20 cm above the manometrically determined lower 
esophageal sphincter (LOS) and the six impedance sensors were placed at 3, 5, 7, 9, 15 
and 17 cm above the LOS. All subjects were asked to record symptoms, meal times and 
periods of recumbency.
All tracings were reviewed manually to ensure accurate reflux detection.  Proximal reflux was 
defined as refluxate reaching the 20 cm pH and or 17-cm impedance sensor. Symptom 
index (SI) and Symptom Association Probability (SAP) were used to characterise the 
association between symptoms and reflux.
Saliva sample collection and analysis  
In order to identify the optimal timing of saliva sampling for pepsin analysis all subjects were 
asked to collect saliva samples; 2, 5, 10, 15, 30 and 60 minutes after reflux symptoms and 
after activation of the proximal reflux alarm.  Since reflux is common after meals and periods 
of recumbency subjects were also asked to collect similarly timed saliva samples on rising in 
the morning (before eating, drinking or teeth brushing) and after the evening meal. Saliva 
was collected following RD Biomed sampling and packaging instructions and using their 
buffer (0.5 ml of 0.01 M citric acid) and were stored as recommended (4°C) and returned at 
the end of the 24-hour study period on the same working day (as per RD Biomed sampling 
instructions).  All samples were coded and analyses were performed blind to all clinical and 
physiological variables. For the extended study all salivary samples were homogenised by 
vortex mixer and split in two, one half sent for Peptest analysis (Peptest, RD Biomed, Hull), 
the second half was quantified for pepsin by ELISA at The University of Sheffield. Samples 
Page 5 of 24 Alimentary Pharmacology & Therapeutic
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
received on ice at The University of Sheffield were frozen immediately and stored at -80°C 
prior to assay.  
Peptest assay All salivary samples were sent to RD Biomed for proprietary analysis of 
pepsin (Peptest, RD Biomed, Hull) which was undertaken as paid service provision (i.e. the 
samples were presented as for diagnosis, not part of a research collaboration). 
Quantification of pepsin by Peptest was provided by RD Biomed as a data sheet via email 
usually with 1-2 working days of the sample being sent. 
ELISA pepsin assay was an indirect ELISA using antiPepsin A monoclonal antibody (Santa 
Cruz sc-365680, raised against an antigen of aa281-324 of Pepsin A). The ELISA was 
calibrated using recombinant human pepsin A (Stratech SCB-RP112894h, which includes 
aa15-388 of Pepsin A). The ELISA was linear when tested in the range from 0-150ng with a 
limit of detection of 2ng. For development and validation of the ELISA see Supplementary 
Online Information (SOI, Section 1). 
Statistical analyses 
Statistics were undertaken as indicated using SPSS 23 (IBM, Armonk, New York, 2015), 
other than Bland and Altman Tests, which were produced using R (3.4.1), with the packages 
BlandAltmanLeh (v 0.3.1) and ggplot2 (v2.2.1).
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RESULTS
Subjects and demographics
Control group: 50 volunteers responded to the advert; 20 (6 male, 14 female, aged 21 to 56 
years) met the inclusion criteria and completed the study, 3 had exclusion criteria, 26 
declined intubation and one was unable to tolerate intubation 
Patient group: 101 patients were approached; 30 (18 male, 12 female, aged 20 to 72 years) 
met the inclusion criteria and completed the study, 49 declined to participate, 13 were 
excluded as they did not meet the symptom criteria, 8 were excluded as the pH study was 
negative at the time of processing the salivary samples and one was unable to tolerate the 
intubations. All the volunteers denied reflux symptoms and all 30 patients reported regular 
heartburn and or regurgitation. Questionnaire scores were significantly different between the 
two groups (GORS: volunteers 0(0-0) versus patients 10(3-15) p < 0.005; HARQ: volunteers 
0(0-9) versus patients 28 (1-65) (p< 0.005). 
All 20 volunteers had esophageal acid exposure times within the normal range (median 
1.0%, range 0 - 3.5%). The 10 volunteers who also underwent MII had values for non-acid 
and gas reflux within the normal range (mean total number of reflux events 14.6). Of the 30 
patients studied 23 had esophageal acid exposure times in excess of the normal range 
(Median 8.85, and range 3.0 (one individual with significant supine reflux)  39%) and were 
classified as having true acid reflux. A further 3 patients had normal acid exposures (Median 
2.85, range 2.6-4.6%) but had abnormal non-acidic reflux (Median 81, range 74-101 events). 
Four patients were found to have normal reflux values on the day of study and all 
demonstrated a negative SAP and were therefore deemed to have functional heartburn and 
were excluded. A positive SAP was classified as >95%. 
In patients with true acid reflux, 20 reported symptoms during the 24-hour period and in 12 
the proximal reflux alarm was triggered. Manual analysis of the dual pH tracings confirmed 
that such episodes were all associated with both distal and proximal esophageal 
acidification.
Salivary Pepsin analysis
In the initial pilot study, the ten volunteers produced a total of 138 salivary samples for 
Peptest analysis. Seven of the volunteers had detectable levels at reported concentrations of 
25  250 ng/ml, often in multiple samples. Of the seven patients who had true reflux, all had 
detectable levels at concentrations of 25  250 ng/ml in at least one and often in several 
samples. The lack of a clear difference between asymptomatic volunteers and patients 
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prompted us to investigate the validity of the Peptest. We therefore extended the study to a 
further 10 volunteers and 20 patients following an identical protocol but splitting saliva 
samples for analysis by both Peptest and an in-house indirect ELISA.
Peptest analysis of 276 samples from the 20 volunteers revealed detectable levels in 102 
samples in total (37%).  75 % of volunteers had at least one positive sample for salivary 
pepsin (range 1-18 positive samples). Peptest analysis of 458 samples from 25 of the 30 
patients with true reflux revealed positive results in 41 % of samples.  84 % of patients had 
at least one positive result. The indirect ELISA of 141 samples from the 10 volunteers 
revealed detectable levels in 122 samples (87 %). All 10 (100 %) of volunteers had at least 
one positive sample for salivary pepsin. Analysis of 393 samples from 20 patients with 
pathological reflux revealed positive results in 309 (79%) of samples.  All 20 (100 %) of 
patients had at least one positive result.
The mean scores and ranges between the asymptomatic control group and the GERD-
diagnosed patients were compared (Fig 1A). Peptest gave a significant difference in score 
between the control and GERD groups, but the controls gave the higher reading (t-test, 
p<0.01). In contrast, there was no significant difference in the average pepsin concentration 
in each group by ELISA. There were significant differences between the readouts of the two 
quantitation methods within groups (Mann-Whitney, p<0.01 for Control arm, p<0.001 for 
GERD arm). 
To assess whether timing of sampling influenced outcome the data were also analysed 
according to sampling point (rising, post-prandial, post-alarm, post symptoms), and 
differences between groups tested. Peptest quantitations (Fig 1B) were not significantly 
different between patients and volunteers after rising or evening meal, but were significantly 
lower in the patient group on reflux alarm (p<0.05, without Bonferroni correction). A 
comparison was undertaken between Peptest scores for 2-60 minutes following reflux alarm 
in controls and patients (Fig1C). The Peptest results showed no difference in salivary 
readout across time, but symptomatic individuals had lower readouts than the control group 
(P<0.05, one way ANOVA). We assessed the value Peptest as a diagnostic tool using a 
receiver-operator (ROC) analysis (Figs 1D). Peptest yielded an area-under-the-curve of 
0.528 with P=0.333 indicated the test is worthless. 
 Finally, a linear mixed model 18was deployed to assess contributions to variance allowing for 
the repeated nature of measures with respect to time using a First Order autoregressive, Fig 
1E. No variable explained significantly any aspect of the variation in data.  In summary, the 
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readouts for Peptest were lower for subjects with diagnosed GERD than for asymptomatic 
controls when all samples were considered. Furthermore Peptest readouts were not 
significantly different in either fasted state or following reflux for subjects with GERD than 
asymptomatic volunteers. 
Comparison of Peptest and ELISA analyses
As distinct outcomes were found for the Peptest and ELISA analyses (see section 2) direct 
comparisons were undertaken between the quantitations from the two analyses. 
Quantifications were compared in several ways (Fig 2). Quantitations from each method 
were plotted against each other and their relationship tested using a Spearmans correlation 
undertaken (Fig 2A). This test did not indicate any statistically detectable relationship 
between the outcomes from each test. 
As the data did not correlate we assessed their distributions independently. The ELISA data 
followed a biologically usual gamma-distribution (SOI section 2). The Peptest data did not 
follow a gamma distribution and show large frequencies outside the measurement limits 
(SOI, Section2): the data were in a range of 0-500ng, but 73% of the points were outside the 
limits of the sensitivity of measure (63% below and 10% above). To try to identify 
relationships, data were split into three categories according to Peptest result (0, 500 and 
0<datapoint<500). The distributions of ELISA data for each Peptest category were analysed 
and shown to have no significant difference (SOI, Section 2). Bland-Altman analysis is a 
standard statistical option for comparing between two tests of the same endpoint, and was 
used to assess whether the assays were measuring the same substance (Fig 2Bi and ii). 
The plots shows a cluster of datapoints where both tests are at their minimal point. Fig2Bi 
presents untransformed data which exhibit poor distribution due to the narrow range. Data 
were therefore log transformed (Fig 2Bii). Whilst the distribution is wider, the paucity of data 
in the sensitive range for Peptest distorts the graph. Intraclass Correlations (ICC) were 
undertaken for both the untransformed and log transformed data. For the untransformed 
data the ICC is 0.019 (p=0.414) for the transformed data the ICC is 0.54 (p=0.268). These 
ICC data suggest that the two tests are not measuring the same endpoint. As the ELISA is 
undertaken with a commercially validated antibody, revalidated against recombinant pepsin, 
shown to be linear for pepsin, and follows a biologically common gamma distribution, we 
deduce that it is reliably measuring pepsin. We therefore infer that Peptest is not measuring 
pepsin.
Evaluation of salivary pepsin and Peptest as a diagnostic markers for GERD
The ELISA quantitations were then independently assessed in terms for potential to predict 
GERD. When ELISA quantitations were assessed globally, there was no significant 
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difference between the amount of pepsin diagnosed and asymptomatic individuals (Fig 3A). 
As for the Peptest analyses, quantitative data for pepsin were stratified by sampling time 
(rising, postprandially, after alarm and after symptoms). There were no significant 
differences in salivary pepsin concentration at any of these timepoints (Fig 3B). When pepsin 
was analysed in the time period following a reflux alarm there were no significant differences 
between volunteers and patients, and no significant changes across time (Fig 3C). Finally, 
the data were dichotomised as RD Biomed have suggested a diagnostic threshold of 
16ng/ml 17, which demonstrated rates of positives were identical in the GERD and control 
groups (SOI, Section 3). Levels of pepsin in saliva did not discriminate between 
asymptomatic subjects and patients diagnosed with GERD in any experimental setting. 
Finally we assessed the value of the Pepsin ELISA as a diagnostic tool using ROC analysis 
(Fig 3D). The area-under-the-curve analysis was 0.522 with P=0.448 indicating that the test 
is worthless. 
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DISCUSSION
Peptest is a highly promoted diagnostic device presented for assessment of reflux through 
detection of pepsin. It utilizes a proprietary monoclonal antibody (only available to RD 
Biomed) in a lateral flow format to quantify levels of pepsin in saliva (based on the working 
hypothesis that pepsin in saliva is non-routine and can only be attributed to reflux). A recent 
review of studies assessing salivary pepsin for LPR 19 erred to a conclusion that pepsin may 
be of value, however studies were inconsistent with multiple methodologies deployed, a 
range of cut-offs and differences in study design and in control populations. Only one study 
using Peptest was of sufficient rigour for inclusion in that systematic review  12 reporting that 
Peptest yielded the same rates of positives in cases and controls of LPR.
Our initial aim was to establish optimal timings for saliva sampling relative to diurnal variation 
and to measure spiking and persistence of pepsin in saliva following reflux to support optimal 
application of Peptest. However a very high rate of false positives (and negatives) relative to 
clinical diagnostic criteria led to re-evaluation of both Peptest and pepsin data in the context 
of GERD specifically. Our finding is that pepsin is present in control, asymptomatic subjects 
and at measurable levels and does not have discriminatory potential for separating GERD 
from controls. This finding is consistent with other reports which found no difference between 
cases and controls 9,20,21, or found controls had higher levels 22. A recently published study 
concluded a value for Peptest in predicting GERD, however there was no difference 
between controls and GERD patients when all sampling was taking into account, suggesting 
low reproducibility 10. A second recent paper assessing application of Peptest in GERD also 
showed poor reproducibility of Peptest and depended on data-selection to achieve any 
diagnostic power17. Peptest outcomes were provided to us by RD Biomed as a quantification 
in ng/ml of pepsin in saliva. When analysed, the distribution of these data was very skewed 
(Fig 2). As the analytical platform is a window in a lateral flow device, there may be very 
significant potential for subjective score or operator error.
The presence of pepsin in saliva is thought to be indicative of gastric refluxate and is the 
premise of test development, however recent data arising from the Fantom5 project 23 
indicates expression of pepsin in the tongue (SOI, section 3). This outcome from a high-
throughput screen requires direct validation but provides a plausible explanation for 
presence of pepsin in saliva in controls as an apparent inconsistency reported across 
several studies. 
A recent review and guideline advises the use of a constellation of scores in diagnosis of 
GERD and shifts away from a single measure 24. Our report demonstrates inconsistencies 
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between ELISA quantitations (using a validated commercial antipepsin antibody, re-validated 
and calibrated against pepsin from a different supplier) and Peptest quantitations, and 
demonstrated an unusual distribution of data for Peptest by two separate statistical tests. 
Further recent work questions the diagnostic value of Peptest / pepsin25. As far as we can 
determine using a formal statistical test, Peptest and our pepsin ELISA are measuring 
differing analytes. We suggest that Peptest is neither useful as a diagnostic for GERD, nor is 
a measure of pepsin. 
CONCLUSIONS
 There is an unmet need for non-invasive diagnostics for GERD, salivary pepsin has 
been proposed as one such test;
 Our data and those of others indicate pepsin does not discriminate effectively 
between healthy asymptomatic controls and patients with confirmed reflux;
 Our data suggest that Peptest does not reliably measure pepsin. 
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LEGENDS
Figure 1. Analysis of discrimination between patients and controls by Peptest. 
Panel A shows a comparison of Peptest quantitations for all samples for the controls (open 
circles) and GERD patients (closed circles). The average in controls was significantly higher 
than patients (p<0.005, unpaired t-test).  Panel B compares the mean readout for Peptest, 
stratified by sampling time and by patients (grey filled bars) or controls (white bars). There 
was no significant difference between patients and controls at any time except following the 
reflux alarm, when controls were higher than patients. No controls reported a reflux 
symptom, so no comparison was undertaken.  Panel C shows Peptest readout across the 60 
minutes following reflux alarm for controls (open circles) and patients (filled circles). There 
was no significant difference across time. Patients scores were significantly and consistently 
lower than controls (P,0.05, 1-way ANOVA). Event rate was very low in the control group 
with no self-reported symptoms and only three alarms across the study.  Panel D Receiver-
Operator Curve (ROC) analyses of Peptest data. The dataset had an AUC of 0.53 
(P=0.333). Panel E shows variance component analysis using multi-level modelling 
(Repeated Measures ANOVA) for GERD patients and with regards to event type and sample 
time using a First Order autoregressive (SPSS 24). The results demonstrate no significance 
except when sample taken during a reflux event. 
Figure 2. Comparison of Peptest and pepsin ELISA. 
Panel A shows Spearmans correlation between quantifications of pepsin in Saliva from both 
Peptest (x-axis) and indirect ELISA (y-axis). Correlation yielded a very weak r2, of 0.0007, 
which was not significant. Panel B shows Bland-Altman plots for the same comparison: 
Panel Bi is untransformed data (Intraclass correlation (ICC)=0.019, P=0.414), Panel Bii is 
log-transformed data (ICC=0.54, P=0.268). 
Figure 3. Pepsin does not predict GERD 
Panel A shows a comparison of ELISA pepsin quantitations for all samples for the controls 
(open circles) and GERD patients (closed circles). There was no difference between groups 
(unpaired t-test). Note the difference in dynamic range of these data (0-100) by comparison 
with Peptest scores (Fig1A, range 0-600)
Panel B compares the mean readout for pepsin, stratified by sampling time and by patients 
(grey filled bars) or controls (white bars). There was no significant difference between 
patients and controls at any time. No controls reported a reflux symptom, so no comparison 
was undertaken.  Panel C shows pepsin ELISA readout across the 60 minutes following 
reflux alarm for controls (open circles) and patients (filled circles). There was no significant 
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difference across time (1-way ANOVA). Panel D Receiver-Operator Curve (ROC) analyses 
of pepsin ELISA data. The dataset had an AUC of 0.52 (P=0.448).
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Section 1  Pepsin ELISA Development
Determination of specificity of anti-pepsin monoclonal antibody.
Available monoclonal antibodies were surveyed for those with good user ratings, and proven application 
in both western immunoblot and ELISA. Santa Cruz sc-365680 was selected. The sensitivity of the 
antibody was determined in both immunoblot and ELISA.
Left Panel  For immunoblot assessment recombinant human pepsin A was loaded at 0-100ng into SDS-
PAGE. The antibody cross-reacted with a single band (although breakdown products were detected at 
high antigen concentrations). The LoD for immunoblotting appeared to be <10ng. 
Right Panel For ELISA, an indirect ELISA was developed and plates were coated with 0-40ng of 
recombinant pepsin, cross reactions were visualised with horseradish peroxidase conjugated anti-mouse 
secondary antibody. A linear relationship was observed in the 1-40ng range.
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Section 2  Comparison of Peptest and ELISA results
The distributions of data from 499 salivary analyses for pepsin ELISA and for Peptest are shown below. 
Peptest returned a large number of 0 scores which were converted to 8 (half of the stated limit of 
detection) in order to process the data. Pepsin ELISA follows a classical gamma distribution, whereas the 
Peptest data is hyperskewed with 73% of datapoints at either minimus or maximus. Panel C shows the 
distribution of pepsin quantifications according to three strata of Peptest scores (Upper boundary, lower 
boundary and sensitive range). There is no evidence of a significant difference in the distribution of 
pepsin ELISA data in these three categories (Kruskall Wallis=0.627. p=0.731).
Pepsin level (ng/ml) from ELISA (zeros and below coded to 1)
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Section 3  Dichotomous analyses of Peptest and ELISA results according 
to RD Biomeds suggested thresholds
The data from Peptest and ELISA scores were dichotomised at 16ng/ml (RD Biomeds suggested 
diagnostic threshold) and were compared (Panel A). The rates of postives in the Control and GORD 
group are the same using this threshold by both methods. The Peptest data are hyperskwed: when only 
values of 0 were considered (Panel B), there was no difference in the negative score rate between GORD 
patients and controls. When only values att he upper limit of quantification were considered (Panel C) 
there are more positives in the control group.
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Section 3  Expression of pepsinogen in tongue
Expression analysis was undertaken for the expression profile of pepsin (the precursor peptide 
pepsinogen is shown). Analysis shown below indicates expression includes the tongue, suggesting 
potential for oral pepsin antigens. Expression Atlas accessed on 21st March 2018. 
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